What Is Premenstrual Dysphoric Disorder?
Premenstrual Dysphoric Disorder (PMDD) is a neuroendocrine condition recognized by the DSM-5 as a depressive disorder. It is characterized by severe emotional and physical symptoms that occur cyclically in the luteal phase of the menstrual cycle — typically in the 7 to 10 days before menstruation — and remit a few days after the onset of flow.
PMDD is fundamentally different from common premenstrual syndrome (PMS). While PMS affects up to 80% of women with mild to moderate symptoms, PMDD is a psychiatric condition that causes intense suffering and significant functional impairment. It is as disabling as major depression during symptomatic days.
Despite its severity, PMDD remains underdiagnosed. Many women suffer for years before receiving the correct diagnosis, with their symptoms frequently minimized as "just PMS" or "emotional exaggeration". Recognizing PMDD as a legitimate medical condition is the first step toward proper treatment.
Neuroendocrine Sensitivity
PMDD results from abnormal brain sensitivity to normal steroid hormone fluctuations — hormone levels are normal, but the brain response is altered.
Cyclical Pattern
Symptoms are predictable: they emerge in the luteal phase and disappear with menstruation. This cyclical pattern is the diagnostic key.
Treatment Available
SSRIs, hormonal contraceptives, and non-pharmacologic interventions can reduce symptoms in 60-80% of patients.
Pathophysiology
The pathophysiology of PMDD is complex and involves an abnormal central nervous system sensitivity to fluctuations of ovarian steroid hormones — specifically progesterone and its metabolite allopregnanolone. The hormonal levels themselves are normal; what differs is how the brain responds to these variations.
Allopregnanolone and the GABAergic System
Allopregnanolone, a metabolite of progesterone, is a positive modulator of the GABA-A receptor — the main inhibitory neurotransmitter in the brain. In women without PMDD, allopregnanolone produces a calming and anxiolytic effect. In women with PMDD, there is a paradoxical response: instead of calming, allopregnanolone triggers anxiety, irritability, and dysphoria.
This paradoxical response appears to involve alterations in GABA-A receptor subunit composition. Cyclical hormonal fluctuations change the expression of these subunits, producing altered sensitivity that explains the recurrent symptoms.
Serotonergic System
Serotonin also plays a central role. Women with PMDD show reduced serotonergic activity in the luteal phase, which contributes to irritability, depression, and food cravings. This explains the efficacy of SSRIs, which in these cases work differently — with onset of action in hours to days, not weeks as in depression.
Symptoms
The symptoms of PMDD are intense, cyclical, and disabling. They emerge in the second half of the menstrual cycle (luteal phase) and disappear in the first days of menstruation. The contrast between the asymptomatic phase and the symptomatic phase is striking — the woman feels like "another person" during the premenstrual period.
Symptoms of PMDD
- 01
Intense emotional lability
Abrupt mood changes — sudden crying, extreme rejection sensitivity, intense irritability. The woman may recognize the reaction is disproportionate but cannot control it.
- 02
Marked irritability or anger
Anger outbursts and recurrent interpersonal conflicts during the luteal phase. One of the most common and impactful complaints in relationships.
- 03
Depressed mood or hopelessness
Profound sadness, sense of worthlessness, hopelessness. In severe cases, may include cyclical suicidal ideation — which emerges and disappears with the cycle.
- 04
Anxiety and tension
Sensation of being "on the edge of exploding", constant nervousness, difficulty relaxing. May include panic attacks.
- 05
Decreased interest in activities
Loss of motivation for work, exercise, and social activities. Social isolation during the symptomatic phase.
- 06
Difficulty concentrating
Mental fog, forgetfulness, difficulty maintaining focus. Directly impacts professional and academic performance.
- 07
Physical symptoms
Mastalgia, abdominal distension, headache, joint/muscle pain, weight gain from water retention, food cravings (especially for carbohydrates).
- 08
Changes in sleep and energy
Hypersomnia or insomnia, intense fatigue unrelieved by rest.
Diagnosis
PMDD diagnosis requires prospective symptom documentation over at least two consecutive menstrual cycles. The symptom diary is the main diagnostic tool. There are no laboratory tests that confirm the diagnosis — hormonal levels are typically normal.
🏥DSM-5 Criteria for PMDD
Fonte: American Psychiatric Association — DSM-5
Criterion A: At least 5 symptoms in the week before menstruation
At least 1 of the 4 symptoms above must be present- 1.Marked affective lability (mood swings, sudden crying)
- 2.Marked irritability or anger, or increased interpersonal conflicts
- 3.Marked depressed mood, hopelessness, or self-deprecating thoughts
- 4.Anxiety, tension, or sensation of being "on edge"
Additional symptoms (to complete 5 in total)
- 1.Decreased interest in usual activities
- 2.Subjective difficulty concentrating
- 3.Lethargy, fatigue, or marked loss of energy
- 4.Significant change in appetite, overeating, or food cravings
- 5.Hypersomnia or insomnia
- 6.Sense of being overwhelmed or out of control
- 7.Physical symptoms such as mastalgia, joint pain, abdominal distension
Additional mandatory criteria
- 1.Symptoms cause clinically significant distress or functional impairment
- 2.Are not an exacerbation of another disorder (depression, GAD)
- 3.Confirmed by prospective recording of at least 2 cycles
PMDD VS. PMS VS. DEPRESSION
| FEATURE | PMS | PMDD | MAJOR DEPRESSION |
|---|---|---|---|
| Prevalence | ~80% | 3-8% | ~10-15% |
| Severity | Mild to moderate | Severe | Moderate to severe |
| Emotional symptoms | Mild | Intense and disabling | Persistent |
| Temporal pattern | Premenstrual | Strictly luteal | Continuous (≥2 weeks) |
| Postmenstrual remission | Yes | Yes — complete | No |
| Suicidal ideation | Rare | May occur cyclically | May be persistent |
| Functional impairment | Minimal | Significant | Significant |
DIAGNÓSTICO DIFERENCIAL
Differential Diagnosis
Premenstrual Syndrome (PMS)
- Milder symptoms than PMDD
- No significant impact on functionality
- Less prominent mood involvement
Testes Diagnósticos
- Prospective symptom diary for 2 months
Depression with Cyclical Variation
Read more →- Depressive symptoms present throughout the cycle (not only luteal phase)
- Premenstrual worsening of preexisting depression
Testes Diagnósticos
- Prospective diary
- PHQ-9
Bipolar Disorder Type II
- Cyclothymia not linked to the menstrual cycle
- Hypomanic episodes
- Family history
Testes Diagnósticos
- Clinical interview
- MDQ
Endometriosis
- Severe dysmenorrhea
- Dyspareunia
- Infertility
- Cyclical pelvic pain + infertility = gynecologic evaluation
Testes Diagnósticos
- Laparoscopy
- Pelvic MRI
Hypothyroidism
- Worsening of symptoms without clear cyclical correlation
- Chronic fatigue, weight gain
- Elevated TSH
Testes Diagnósticos
- TSH
- Free T4
PMDD vs. PMS and Depression with Cyclical Variation
Distinguishing PMDD from PMS and from depression with premenstrual worsening is fundamental and requires prospective monitoring for at least 2 months. In PMS, physical and emotional symptoms are mild to moderate without significant functional impact. In PMDD, symptoms are severe — especially mood symptoms: intense irritability, markedly depressed mood, severe anxiety — with clear functional impact in at least one cycle.
Major depression with premenstrual worsening is frequently confused with PMDD. The diagnostic key lies in the temporal pattern: in PMDD, symptoms occur ONLY in the luteal phase (1-2 weeks before menstruation) and remit completely within a few days of menstrual onset. If depressive symptoms are present throughout the entire cycle — only worsening premenstrually — the primary diagnosis is major depression. A prospective symptom diary is mandatory for this distinction.
Bipolar Disorder and Cyclothymia
Bipolar disorder type II may mimic PMDD when affective cycles coincide with the menstrual cycle. BD II includes hypomanic episodes (increased energy, decreased need for sleep, impulsive behavior) that do not occur in PMDD. The MDQ (Mood Disorder Questionnaire) and a detailed clinical interview covering prior episodes and family history guide the distinction. BD II patients who receive SSRIs without a mood stabilizer may experience a manic switch.
Cyclothymia — the milder form of the bipolar spectrum — presents with chronic, oscillating mood changes that do not necessarily follow the menstrual cycle, though they may worsen premenstrually. The minimum 2-year duration of subthreshold mood symptoms distinguishes cyclothymia from PMDD. When a bipolar diagnosis is in doubt, psychiatric evaluation is recommended before starting SSRI monotherapy.
Endometriosis and Gynecologic Conditions
Endometriosis causes intense dysmenorrhea, dyspareunia (pain during sexual intercourse), chronic pelvic pain, and frequently infertility — physical symptoms that can be components of PMDD or a separate diagnosis. Premenstrual and menstrual worsening of physical symptoms can be confused with PMDD. With severe dysmenorrhea, chronic pelvic pain, or difficulty becoming pregnant, specialized gynecologic evaluation is mandatory — laparoscopy or pelvic MRI may identify endometriosis foci.
Conditions such as uterine fibroids and polycystic ovary syndrome (PCOS) may also cause symptoms that overlap with PMDD. PCOS is associated with menstrual irregularities, hyperandrogenism, and insulin resistance, which may contribute to mood changes. Pelvic ultrasound and hormonal evaluation (FSH, LH, androgens, insulin) are indicated when an underlying gynecologic condition is clinically suspected.
Treatment
PMDD treatment is based on three main pillars: serotonergic modulation (SSRIs), ovulation suppression, and non-pharmacologic interventions. The choice depends on the severity of symptoms and patient preferences.
SSRIs — First-Line Treatment
Selective serotonin reuptake inhibitors are the treatment with the best evidence for PMDD. Unlike depression, in PMDD SSRIs may work at low doses and with rapid onset of action (hours to days). They may be used continuously or only during the luteal phase (intermittent dosing).
PHARMACOLOGIC OPTIONS FOR PMDD
| TREATMENT | DOSING | EFFICACY | CONSIDERATIONS |
|---|---|---|---|
| Continuous SSRI (Sertraline, Fluoxetine) | Daily throughout the cycle | 60-70% response | First line — well tolerated, possible sexual side effects |
| Intermittent SSRI | Only in the luteal phase (14 days) | 50-60% response | Fewer side effects, but may be less effective for physical symptoms |
| Drospirenone-containing contraceptives | 24/4 regimen (continuous) | 40-50% response | Partially suppresses ovulation — useful when contraception is desired |
| GnRH agonists | Monthly injection | 80-90% response | Reserved for refractory cases — chemical menopause side effects |
Cycle 1-2
Prospective documentation of symptoms with menstrual diary. Psychoeducation. Non-pharmacologic measures: aerobic exercise, calcium 1,200 mg/day, vitamin B6.
Cycles 3-4
Start SSRI (continuous or intermittent). Assess response after 2 treatment cycles.
Cycles 5-8
Adjust dose or change strategy if response is insufficient. Consider hormonal contraception if SSRI is ineffective.
6-12 months
Maintain effective treatment. Periodically review the need for ongoing treatment.
Acupuncture as Treatment
Acupuncture has been studied as a complementary therapy for premenstrual symptoms. Proposed mechanisms — still hypothesized and under investigation — include possible modulation of the serotonergic system, influence on the hypothalamic-pituitary-gonadal (HPG) axis, effects on inflammatory cytokines, and on the autonomic nervous system.
Preliminary studies suggest acupuncture may help relieve symptoms such as irritability, pain, abdominal distension, and mood changes in some patients. Hypothesized modulation of the luteal-phase inflammatory response and endorphin release are proposed mechanisms that may benefit some PMDD patients, especially those who do not tolerate drug treatment or prefer to complement it — always under the attending physician's guidance.
Acupuncture is most often used as a complement to pharmacologic treatment, or as an option for women with mild to moderate symptoms who prefer non-pharmacologic approaches. Sessions scheduled in the luteal phase may offer greater benefit.
Prognosis
Untreated, PMDD persists throughout reproductive life. With adequate treatment, 60-80% of women show significant improvement in symptom severity and functionality. Symptoms cease naturally with menopause, when ovarian hormonal fluctuations end.
Women with PMDD have an increased risk of developing major depression and peripartum depressive disorder. Follow-up during pregnancy and the puerperium is important. Perimenopause may bring a period of transient symptom worsening due to hormonal irregularity.
Early diagnosis and adequate treatment are essential to avoid cumulative impact on professional life, relationships, and self-esteem. Many women report a transformative improvement in quality of life after correct treatment.
Myths and Facts
Myth vs. Fact
PMDD is the same thing as PMS — every woman has it.
PMS affects up to 80% of women with mild symptoms. PMDD is a psychiatric condition affecting 3-8% of women, with severe symptoms that cause significant functional impairment. The difference lies in severity and impact — comparable to the difference between normal worry and an anxiety disorder.
Myth vs. Fact
It's just 'silliness' or 'emotional exaggeration'.
PMDD has a documented neurobiologic basis. It involves altered GABA-A receptor sensitivity to ovarian steroids, cyclical serotonergic dysregulation, and inflammatory activation. 15% of women with PMDD attempt suicide over their lifetime — clearly not an exaggeration.
Myth vs. Fact
Hormones are dysregulated — just 'balance the hormones'.
Hormone levels in women with PMDD are normal. The problem lies not in the hormones themselves, but in the brain's abnormal sensitivity to normal hormonal fluctuations. Therefore, measuring hormones does not aid diagnosis, and simple hormone replacement does not treat the condition.
When to Seek Help
If you recognize a cyclical pattern of intense emotional symptoms that emerge before menstruation and disappear after menstrual onset, seek a professional familiar with PMDD. You do not need to suffer in silence — effective treatments exist.
Frequently Asked Questions about PMDD
PMDD is a hormone-based mood disorder recognized in the DSM-5, characterized by severe psychological and physical symptoms that occur in the luteal phase of the menstrual cycle (1-2 weeks before menstruation) and remit completely within a few days of menstrual onset. It differs from PMS (Premenstrual Syndrome) in severity: symptoms cause significant functional impairment at work, in relationships, and in quality of life. It affects approximately 3-8% of women of reproductive age.
Premenstrual Syndrome (PMS) and PMDD differ in intensity and impact. In PMS, symptoms are mild to moderate — bothersome but not impairing normal functioning. In PMDD, symptoms are severe and disabling: intense irritability or anger that disrupts relationships, markedly depressed mood, severe anxiety, or extreme mood swings — across at least 5 of the 11 defined symptoms, with at least one being a mood symptom. Significant functional impact is the key differential criterion.
Diagnosis requires prospective symptom documentation over at least 2 consecutive cycles — not just retrospective report, which is imprecise. The Daily Record of Severity of Problems (DRSP) and the Calendar of Premenstrual Experiences are validated tools. Symptoms must be present in the luteal phase, remit after menstrual onset, and be absent in the follicular phase (the week after menstruation). Hormonal tests are not diagnostic — hormone levels are normal in PMDD.
PMDD is not caused by abnormal hormone levels — women with PMDD have normal estrogen and progesterone levels. The cause is abnormal central nervous system sensitivity to the cycle's normal hormonal fluctuations. Specifically, PMDD is associated with increased GABA sensitivity modulated by allopregnanolone (a progesterone metabolite) and with alterations in the serotonergic system during the luteal phase. Genetic factors contribute — heritability is estimated at 50%.
First-line treatments are SSRIs, used continuously or only in the luteal phase (2 weeks before menstruation). Fluoxetine, sertraline, and escitalopram have the strongest evidence. Response rate: 60-75%. Oral contraceptives with drospirenone + ethinylestradiol (e.g., Yaz) are specifically approved for PMDD. Non-pharmacologic treatments with evidence include aerobic exercise, calcium supplementation (1,200 mg/day), vitamin B6, and reduced caffeine and alcohol intake. Acupuncture also has favorable evidence.
Yes — this is one of the pharmacologic particularities described for PMDD. Unlike major depression, some studies indicate that SSRIs taken only in the luteal phase may offer faster response, in some cases as early as the first cycle. The mechanistic hypothesis involves acute regulation of the GABAergic system modulated by the neurosteroid allopregnanolone. Decisions about continuous or intermittent use, drug choice, and dose are always up to the physician — they should not be self-managed.
Preliminary studies and systematic reviews suggest acupuncture may help reduce PMDD symptoms — especially irritability, depressed mood, abdominal distension, and mastalgia — though the methodological quality of the trials remains limited. Proposed mechanisms (under investigation) include possible modulation of the autonomic nervous system, effects on neurotransmitters (serotonin, GABA, endorphins), and effects on the hypothalamic-pituitary-ovarian axis. Physician acupuncturists use protocols adapted to the menstrual cycle as a complement to conventional treatment, never as a substitute for SSRIs or other prescribed drugs.
Many women report progressive symptom worsening over the reproductive years. PMDD frequently intensifies in pre-menopause (perimenopause), when hormonal fluctuations become more erratic. The good news: symptoms generally disappear with menopause — when cyclical fluctuations cease. Symptoms also disappear during pregnancy. On the other hand, some women develop PMDD after pregnancy or when changing contraceptives.
Yes, significantly. Intense mood symptoms — irritability, impulsive conflicts, easy crying, perceived rejection — affect intimate, family, and work relationships. Many women report regret over decisions or arguments made during the luteal phase. Recognizing the cyclical pattern helps the patient and her partners contextualize the symptoms. Management includes communication strategies adapted to the cycle, postponing important decisions to the follicular phase, and psychoeducation for partners.
Seek medical evaluation if: premenstrual symptoms significantly affect your work, relationships, or quality of life; you notice a clear cyclical pattern of severe mood symptoms; you have thoughts of self-harm during the premenstrual phase — seek immediate help in this case; or lifestyle measures (exercise, reduced caffeine) have not been sufficient. A gynecologist or primary care physician can initiate the investigation; complex cases can be referred to psychiatry.
Related Reading
Deepen your knowledge with related articles